Abstract
Antisense therapy represents a novel genetic-based therapeutic approach, initiated by Zamecnik et al. about 20 years ago (1). The rationale for antisense oligonucleotide therapeutics is straightforward: to identify a specific inhibitor of an mRNA of interest on the basis of the nucleotide sequence of the mRNA and design a complementary oligonucleotide (oligo). Thus, antisense approaches offer the possibility of specific, rational drugs. Over the years, although there have been many concerns that have limited enthusiasm for the development of these drugs from the preclinical to the clinical level (2,3), significant advances have been made in this field of research. The development of improved synthetic methods yielding sufficient quantities of antisense oligos has allowed extensive preclinical and clinical pharmacologic and toxicologic studies. Advanced antisense chemistry providing various modifications of oligos has resulted in improved pharmacokinetic, pharmacodynamic, and toxicologic profiles of antisense oligos. Extensive studies examining both specific and non-specific effects of oligos have led to a better design of antisense sequences to target genes. More recently, several antisense oligos have entered clinical use or clinical trials, including those targeted to genes important in human cancers (4–10), with the first antisense drug Vitravene being approved for the treatment of patients with cytomegalovirus-induced retinitis (5). Research in the antisense field has been reviewed periodically (3–9).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zamecnik, P.C. (1996) History of antisense oligonucleotides, in Antisense Therapeutics (Agrawal, S., ed.), Humana Press, Totowa, NJ, pp. 1–12.
Stein, C. A. and Cheng, Y. C. (1993) Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 261, 1004–1012.
Diasio, R. B. and Zhang, R. (1997) Pharmacology of therapeutic oligonucleotides. Antisense Nucl. Acid Drug Dev. 7, 239–243.
Agrawal, S. (1996) Antisense oligonucleotides: towards clinical trial. Trends Biotech. 14, 376–387.
Crooke, S. T. (1998) Antisense Research and Applications, Springer-Verlag, Berlin.
Wickstrom, E. (1998) Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, Marcel Dekker, New York.
Kushner, D. M. and Silverman, R. H. (2000) Antisense cancer therapy: the state of the science. Curr. Oncol. Rep. 2, 23–30.
Monia, B. P., HolmLund, J., and Dorr, F. A. (2000) Antisense approaches for the treatment of cancer. Cancer Invest. 18, 635–650.
Gewirtz, A. M. (2000) Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18, 1809–1811.
Zhang, R. and Wang, H. (2000) Antisense oligonucleotides as anti-tumor therapeutics. Recent Res. Dev. Cancer 2, 61–76.
Zhang, R., Yan, J., Shahinian, H., et al. (1995) Pharmacokinetics of an oligodeoxy-nucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58, 44–53.
Zhang, R., Diasio, R. B., Lu, Z., et al. (1995) Pharmacokinetics and tissue disposition in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharm. 49, 929–939.
Zhang, R., Lu, Z., Zhao, H., et al. (1995) In vivo stability, disposition, and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50, 545–556.
Zhang, R., Iyer, P., Yu, D., et al. (1996) Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats following intravenous administration. J. Pharm. Exp. Ther. 278, 971–979.
Agrawal, S. and Zhang, R. (1997) Pharmacokinetics of phosphorothioate oligonucleotide and its novel analogs, in Antisense Oligodeoxynucleotides and Antisense RNA as Novel Pharmacological and Therapeutic Agents (Weiss, B., ed.), CRC Press, Boca Raton, FL, pp. 58–78.
Agrawal, S. and Zhang, R. (1997) Pharmacokinetics of oligonucleotides, in Oligonucleotides as Therapeutic Agents. CIBA Foundation Symposium 209, Wiley, Chichester, pp. 60–78.
Agrawal, S. and Iyer, R. P. (1995) Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6, 112–119.
Agrawal, S., Zhang, X., Zhao, H., et al. (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharm. 50, 571–576.
Agrawal, S., Jiang, Z., Zhao, Q., et al. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94, 2620–2625.
Agrawal, S. and Zhang, R. (1998) Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administrations in experimental animals, in Antisense Research and Applications (Crooke, S., ed.), Springer-Verlag, Heidelberg, pp. 525–543.
Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. (1999) Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96, 13,989–13,994.
Chen, H. X., Marchall, J. L., Ness, E., et al. (2000) A safety and pharmackinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusion in patients with refractory solid tumors. Clin. Cancer Res. 6, 1259–1266.
Prives, C. and Hall, P. A. (1999) The p53 pathway. J. Pathol. 187, 112–126.
Piette, J., Neel, H., and Marechal, V. (1997) Mdm2: keeping p53 under control. Oncogene 15, 1001–1010.
Cahilly-Snyder, L., Yang, F. T., Francke, U., and George, D. L. (1987) Molecular anlaysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13, 235–244.
Zhang, R. and Wang, H. (2000) MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Design 6, 393–416.
Momand, J. and Zambetti, G. P. (1997) Mdm-2: “big brother” of p53. J. Cell Biochem. 64, 343–352.
Prives, C. (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5–8.
Lozano, G. and Montes de Oca Luna, R. (1998) MDM2 function. Biochim. Biophys. Acta 1377, M55–M59.
Juven-Gershon, T. and Oren, M. (1999) Mdm2: the ups and downs. Mol. Med. 5, 71–83.
Freedman, D. A., Wu, L., and Levine, A. J. (1999) Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55, 96–107.
Freedman, D. A. and Levine, A. J. (1999) Regulation of p53 protein by MDM2 oncoprotein-Thirty eighth G.H.A. Clowes memorial award lecture. Cancer Res. 59, 1–7.
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) MDM2 expression is induced by wild type p53 activity. EMBO J. 12, 461–468.
Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., and Levine, A. J. (1993) The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 90, 11,623–11,627.
Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998) The MDM2 gene amplification database. Nuc. Acids Res. 26, 3453–3459.
Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., and Uchida, T. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84, 3158–3165.
Landers, J. E., Haines, D. S., Strauss, J. F., and George, D. L. (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9, 2745–2750.
Landers, J. E., Cassel, S. L., and George, D. L. (1997) Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stablized wild-type p53 protein. Cancer Res. 57, 3562–3568.
Dorigo, O., Turla, S. T., Lebedeva, S., and Gjerset, R. A. (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J. Neurosurg. 88, 535–540.
Nielsen, L. L. and Maneval, D. C. (1998) p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5, 52–63.
Bottger, A., Bottger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860–869.
Midgley, C. A. and Lane, D. P. (1997) P53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15, 1179–1189.
Arriola, E. L., Lopez, A. R., and Chresta, C. M. (1999) Differential regulation of p21/waf-1/cip-1 and mdm2 by etoposide: etoposide inhibits the p53-mdm2 autoregulatory feedback loop. Oncogene 18, 1081–1091.
Chen, L., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95, 195–200.
Chen, L., Lu, W., Agrawal, S., Zhou, W. Zhang, R., and Chen, J. (1999) Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5, 21–34.
Wang, H., Oliver, P., Zeng, X., et al. (1999) MDM2 oncogene as a target for cancer therapy: an antisense approach. Intl. J. Oncol. 15, 653–660.
Cai, Q., Lindsey, J. R., and Zhang, R. (1997) Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins, natural product topoisomerase I inhibitors. Int. J. Oncol. 10, 953–960.
Zhang, R., Li, Y., Cai, Q., Liu, T., Sun, H., and Chambless, B. (1998) Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharm. 41, 257–267.
Takimoto, C. H. and Arbuck, S. G. (1996) The camptothecins, in Cancer Chemotherapy and Biotherapy (Chabner, B. A. and Longo, D. L., eds.), Philadelphia: Lippincott Raven Publishers, pp. 463–484.
Liu, W. and Zhang, R. (1998) Upregulation of p21/WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer agents 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int. J. Oncol. 12, 793–804.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Zhang, R., Wang, H. (2003). Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression. In: Buolamwini, J.K., Adjei, A.A. (eds) Novel Anticancer Drug Protocols. Methods in Molecular Medicine, vol 85. Humana Press. https://doi.org/10.1385/1-59259-380-1:205
Download citation
DOI: https://doi.org/10.1385/1-59259-380-1:205
Publisher Name: Humana Press
Print ISBN: 978-0-89603-963-6
Online ISBN: 978-1-59259-380-4
eBook Packages: Springer Protocols